About FSHD Canada Foundation

FSHD clinical trials are coming to Canada – get registered here: Canadian Neuromuscular Disease Registry

Move To A Cure...
A Cure To Move

Funding research to help find a cure for Canadians who suffer from FSHD.

Effect of Matrix Bound Nanovesicles in a rodent model of FSHD: Histomorphologic Analysis

Test period: August 1, 2023 to January 31, 2024 Investigators: George Hussey, PhD and Stephen F. Badylak, DVM, PhD, MD The proposed studies will evaluate the immune and myogenic cell…

Read More

Matrix Bound Vesicles for the Treatment of DUX4-mediated Muscle Pathology

Investigators: Collaborative study between Dr. Michael Kyba (UMN) and Dr. Stephen Badylak (UPMC) This study will investigate the effects of treating muscle with GMP produced matrix-bound vesicles (MBVs) in the iDUX4pA/HSA…

Read More

Phenotypic characterization of FSHD-like FLExDUX4 minipigs

Investigator: Peter L. Jones, PhD, University of Nevada, Reno School of Medicine All forms of FSHD are caused by misexpression of DUX4 (double homeobox protein 4) in skeletal muscles; thus, the…

Read More

Srideep Dey

Kitchener, ON

I was diagnosed with fshd at the age of 10, now I'm 23. I also face the same difficulties, among which climbing staircase is the worst, and I am scared…

Read More


Spruce Grove, AB

I was a diagnosed at the age of 13 (1983). Neither of my parents have nor carry the gene. There is no family history. When I was 23, I had…

Read More

John Mora

Toronto, ON

Good evening, my name is John. I was diagnosed with FSHD Muscular Dystrophy on January of 2015. Before my diagnosis I used to train MMA and kickboxing, live a normal…

Read More

Our Mission

The singular goal of the FSHD Canada Foundation is to help find a cure — as soon as possible — for Canadians who suffer with FSHD.

To accomplish this the Foundation aims to reach out to all Canadians to make them aware of what is going on in FSHD research and to solicit financial support for the critical research required to find a cure. The Foundation will then use these funds to support FSHD research — in Canada and around the world.

Learn More

What is FSHD?

Facioscapulohumeral muscular dystrophy or FSHD is the most prevalent of the nine primary types of muscular dystrophy affecting adults and children. Muscular dystrophy in general connotes a genetic, hereditary muscle disease that causes progressive muscle weakness. FSHD is also broadly characterized as a neuromuscular disease (NMD), as muscular dystrophy is a subset of NMD. Muscular dystrophies are alike in that they cause progressive skeletal muscle weakness, defects in the biochemical, physical and structural components of muscle, and the death of muscle cells and tissue. However, researchers believe that the causes of each of the muscular dystrophies are not necessarily the same.

Learn More

https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca